300142.SZ
Walvax Biotechnology Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 12.16
+0.83%Year over year
Reported trailing growth
- Revenue
- -10.6%
- EBITDA
- —
- EBIT
- +1318.3%
- EPS
- +119.0%
- Free cash flow
- -79.7%
- Operating cash flow
- -33.5%
Forward estimates
Based on analyst estimates
- Revenue
- -31.8%
- EBITDA
- -39.3%
- EPS
- -83.2%
Three-year CAGR
- Revenue
- -22.0%
- EBITDA
- -24.3%
- EBIT
- -44.5%
- Net income
- -37.5%
- EPS
- -37.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026